- Home
- ROIV vs SUM Comparison
ROIV vs SUM Comparison
Compare ROIV & SUM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- SUM
- Stock Information
- Founded
- ROIV 2014
- SUM 2009
- Country
- ROIV United Kingdom
- SUM United States
- Employees
- ROIV N/A
- SUM N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- SUM Mining & Quarrying of Nonmetallic Minerals (No Fuels)
- Sector
- ROIV Health Care
- SUM Industrials
- Exchange
- ROIV Nasdaq
- SUM Nasdaq
- Market Cap
- ROIV 8.8B
- SUM 8.8B
- IPO Year
- ROIV N/A
- SUM 2015
- Fundamental
- Price
- ROIV $11.57
- SUM $50.55
- Analyst Decision
- ROIV Strong Buy
- SUM Buy
- Analyst Count
- ROIV 8
- SUM 15
- Target Price
- ROIV $17.93
- SUM $50.62
- AVG Volume (30 Days)
- ROIV 5.3M
- SUM 5.7M
- Earning Date
- ROIV 02-11-2025
- SUM 02-12-2025
- Dividend Yield
- ROIV N/A
- SUM N/A
- EPS Growth
- ROIV N/A
- SUM N/A
- EPS
- ROIV 5.89
- SUM 0.92
- Revenue
- ROIV $129,128,999.00
- SUM $3,754,547,000.00
- Revenue This Year
- ROIV $15.98
- SUM $58.70
- Revenue Next Year
- ROIV N/A
- SUM $6.28
- P/E Ratio
- ROIV $2.06
- SUM $55.07
- Revenue Growth
- ROIV 145.68
- SUM 49.49
- 52 Week Low
- ROIV $9.69
- SUM $34.38
- 52 Week High
- ROIV $13.06
- SUM $53.49
- Technical
- Relative Strength Index (RSI)
- ROIV 41.56
- SUM 60.21
- Support Level
- ROIV $11.72
- SUM $50.30
- Resistance Level
- ROIV $12.22
- SUM $50.87
- Average True Range (ATR)
- ROIV 0.30
- SUM 0.22
- MACD
- ROIV -0.09
- SUM -0.31
- Stochastic Oscillator
- ROIV 15.24
- SUM 33.22
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About SUM Summit Materials Inc.
Summit Materials Inc is engaged in the production and sale of aggregates, cement, ready-mix concrete, asphalt paving mix and concrete products and owns and operates quarries, sand and gravel pits, two cement plants, cement distribution terminals, ready-mix concrete plants, asphalt plants and landfill sites. It is also engaged in paving and related services. The Company's three operating and reporting segments are the West, East and Cement segments. It operates in 21 U.S. states and in British Columbia, Canada and has assets in 21 U.S. states and in British Columbia, Canada through its platform.